Search
Showing results for "early lung health"
Professor Andrew Whitehouse, the Angela Wright Bennett Professor of Autism Research and CliniKids Director, has been appointed Deputy Director (Research) at The Kids Research Institute Australia.
Congratulations to infectious diseases clinician-researcher Professor Asha Bowen, awarded a Medal of the Order of Australia (OAM) in the King’s Birthday Honours List for her service to medicine in the field of clinical diseases.
Dr Matthew ‘Tepi’ Mclaughlin is the 2022 The Kids Research Institute Australia Aspire Award winner - coordinated by Western Australia’s peak body for business events, Business Events Perth.
The Kids Research Institute Australia has backed a series of transport priorities to keep children safer on the roads, boost physical activity levels, and save the economy billions of dollars.
Skin scar formation following Bacille Calmette-Guérin (BCG) or smallpox (Vaccinia) vaccination is an established marker of successful vaccination and 'vaccine take'. Potent pathogen-specific (tuberculosis; smallpox) and pathogen-agnostic (protection from diseases unrelated to the intentionally targeted pathogen) effects of BCG and smallpox vaccines hold significant translational potential.
Determine the optimal antibiotic choice for lower respiratory tract infection in children with neurodisability.
Following the introduction of jurisdictional maternal pertussis vaccination programs in Australia, we estimated maternal vaccine effectiveness (VE) and whether maternal pertussis vaccination modified the effectiveness of the first 3 primary doses of pertussis-containing vaccines.
Urinary tract infections (UTIs) due to MDR organisms are increasingly common. The lack of paediatric data on efficacious antibiotics makes UTI treatment particularly challenging. Data on the efficacy of fosfomycin use for UTI in children are variable.
Influenza vaccination of children with medical comorbidities is critical due their increased risks for severe influenza disease. In Australia, hospitals are an avenue for influenza vaccine delivery to children with comorbidities but are not always effectively utilised. Qualitative enquiry sought to ascertainment the barriers and enablers for influenza vaccination recommendation, delivery, and recording of these children at Australian hospitals.
We aimed to assess the direct protective effect of 13 valent pneumococcal conjugate vaccine (13vPCV) against invasive pneumococcal pneumonia (IPP; including pneumonia and empyema) in children using a nation-wide case-control study across 11 paediatric tertiary hospitals in Australia.